Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride.
about
Molecular mechanism of copper transport in Wilson disease.Molecular mechanisms of in vivo metal chelation: implications for clinical treatment of metal intoxicationsCopper Homeostasis as a Therapeutic Target in Amyotrophic Lateral Sclerosis with SOD1 MutationsA review and current perspective on Wilson disease.Effect of D-penicillamine treatment on brain metabolism in Wilson's disease: a case study.Spontaneous hepatic copper accumulation in Long-Evans Cinnamon rats with hereditary hepatitis. A model of Wilson's disease.Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.Zinc acetate for the treatment of Wilson's disease.Wilson's disease: clinical presentation and use of prognostic index.Effective treatment of Wilson's disease with oral zinc sulphate: two case reports.Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation.1H NMR-based metabolomics investigation of copper-laden rat: a model of Wilson's disease.Prospective pilot study of a single daily dosage of trientine for the treatment of Wilson diseaseWilson's disease: clinical, genetic and pharmacological findings.Wilson's disease: A review of what we have learned.Novel therapeutic approaches to the treatment of Wilson's disease.Presentation, diagnosis and outcome of predominantly hepatic Wilson's disease in adult Saudi patients: a single centre experience.Advance in the pathogenesis and treatment of Wilson disease.Hereditary iron and copper deposition: diagnostics, pathogenesis and therapeutics.Current Drug Managements of Wilson's Disease: From West to East.Trientine reduces BACE1 activity and mitigates amyloidosis via the AGE/RAGE/NF-κB pathway in a transgenic mouse model of Alzheimer's disease.Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer's diseaseTherapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease.Pathogenesis and management of Wilson disease.Current status in the therapy of liver diseases.The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells.Cell Permeable Au@ZnMoS4 Core-Shell Nanoparticles: Towards a Novel Cellular Copper Detoxifying Drug for Wilson's DiseaseZinc acetate treatment in Wilson's disease.Biocompatible D-Penicillamine Conjugated Au Nanoparticles: Targeting Intracellular Free Copper Ions for Detoxification.Pharmacokinetics, pharmacodynamics, and metabolism of triethylenetetramine in healthy human participants: an open-label trial.A Highly Efficient and Extremely Selective Intracellular Copper Detoxifying Agent Based on Nanoparticles of ZnMoS4.Iron accumulation in the liver of male patients with Wilson's disease.Two male patients with Wilson's disease treated using trientine and iron reduction therapy.Once daily trientine for maintenance therapy of Wilson disease.Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. α-Lipoic acid as a potential anti-copper agent.Neuropsychological and electrophysiological examination of a patient with Wilson's disease.Importance of adequate decoppering in Wilson's disease.Copper chelation by trientine dihydrochloride inhibits liver RFA-induced inflammatory responses in vivo.Penicillamine-related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease.
P2860
Q24812338-88DD95AF-9701-495B-882D-1ACF8B1CBC7CQ24812715-F07F87C3-3D02-4DC3-BCB1-6790E5BC8803Q26748245-745FA370-87DB-439A-8287-BBF0A2AA70BAQ30907824-1EFFDDC6-6891-4B0A-AC2A-716994F13F6BQ33631469-EBDFEA4B-0D78-452E-8659-FB704D40D4C3Q34190413-3DECE5CC-F417-4042-ABD0-30A358F4CDDCQ34282333-BCADF6A2-58DC-4649-9E90-49CB375870A9Q34390366-AC22C3EF-B2FB-44C7-B254-CC380BA68188Q34531677-627E0038-EEA8-4688-8CEE-DDB1AF81313CQ34550762-4AA9B0F8-F09A-489D-BEF3-7D32C271737DQ35136117-BEE94679-FAC9-4A32-8F91-381373DBBB00Q35300486-462B35E8-F7DF-4B03-8E2D-79C1792C19B3Q35594074-BA3CDE32-30B1-4A3E-BC8A-E39FCC191065Q36033407-4BB9FEEA-90A4-4C83-8060-66F868A97065Q36369817-041DC959-254F-47EC-899F-E65DCBE711BAQ36382586-6DEB49AE-AE9B-479F-A4A0-0090B1839DFEQ36404886-D8FCBAE3-5D62-4629-A6F2-77319DEA70A8Q36478429-12DD7C84-846C-4AF7-8944-BAC38A40B458Q36823912-08B410FE-A06F-4E4C-A202-03F87679D006Q36925896-4EB63F94-37DE-47FD-8592-8E244D2D1639Q37406597-15B024A3-87B2-41F3-B0B6-F29F9D23A9B5Q37428097-1E9036C5-A3AD-4AC1-A330-F5954B877356Q37902643-EA88299C-D54A-4993-ABE0-6197DFDE1515Q38180820-EA3F8B06-E1B1-4BC1-A1FB-6FE3D706E46EQ38208508-D03A3BAA-C0A5-498E-8F05-3AE5E6293CDCQ40672172-C7EB5A79-9E22-4916-A739-E4A304CA1E77Q41385070-5F61E8DC-8CAC-4E42-AE85-893F96942FCBQ41707216-112E2CA6-109E-4565-A063-7A8F3DD915D7Q42233172-0543C3D0-635F-45FD-8B89-5A29FF39C344Q42648655-0D8D5C10-ADAD-4A5A-A180-A83E41A26BABQ43201965-5B68E155-6B1A-4FE9-BF73-0F3C3356864BQ43807980-DBF08884-DA1F-4269-B375-26944B1C8FC6Q46712935-CF4DD79B-9F50-4983-9971-83CCFFC5BBCAQ46742236-B0B112F8-796B-4644-AFA8-54AC87395E08Q47843934-61E8DAAB-FD82-4C9D-A965-070FAD88A11DQ48489988-8780FB50-2261-462B-B6C3-7551671A6B33Q48793034-EE7E2C2E-6177-4E7A-A133-6B214F4F4F9EQ48962335-4BD47066-B60F-43FC-B9B0-812516C51449Q50907787-706892F9-04BE-4BF5-9889-AB99650358B7Q51767490-2D1C3AB1-CF09-45CD-8A47-81A40BDFAA52
P2860
Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride.
description
1982 nî lūn-bûn
@nan
1982 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1982 թվականի մարտին հրատարակված գիտական հոդված
@hy
1982年の論文
@ja
1982年学术文章
@wuu
1982年学术文章
@zh-cn
1982年学术文章
@zh-hans
1982年学术文章
@zh-my
1982年学术文章
@zh-sg
1982年學術文章
@yue
name
Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride.
@ast
Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride.
@en
Treatment of Wilson's disease with trientine
@nl
type
label
Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride.
@ast
Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride.
@en
Treatment of Wilson's disease with trientine
@nl
prefLabel
Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride.
@ast
Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride.
@en
Treatment of Wilson's disease with trientine
@nl
P1433
P1476
Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride.
@en
P2093
J M Walshe
P304
P356
10.1016/S0140-6736(82)92201-2
P407
P577
1982-03-01T00:00:00Z